EDX Stock Overview
Engages in developing a range of diagnostics testing solutions in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
EDX Medical Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.09 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | -10.00% |
| 1 Year Change | 60.00% |
| 33 Year Change | 45.16% |
| 5 Year Change | n/a |
| Change since IPO | -10.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| EDX | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -2.7% | -2.2% | -0.1% |
| 1Y | 60.0% | -23.8% | 5.5% |
Return vs Industry: EDX exceeded the UK Healthcare industry which returned -23.8% over the past year.
Return vs Market: EDX exceeded the UK Market which returned 5.5% over the past year.
Price Volatility
| EDX volatility | |
|---|---|
| EDX Average Weekly Movement | 6.4% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EDX has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: EDX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Mike Hudson | www.edxmedical.co.uk |
EDX Medical Group Plc engages in developing a range of diagnostics testing solutions in the United Kingdom. It engages in the development of tests for diabetes, obesity, inflammatory disorders, and kidney and liver disorders. The company was formerly known as TECC Capital PLC and changed its name to EDX Medical Group Plc in November 2022.
EDX Medical Group Plc Fundamentals Summary
| EDX fundamental statistics | |
|---|---|
| Market cap | UK£30.10m |
| Earnings (TTM) | UK£0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs EDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EDX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£0 |
| Earnings | UK£0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EDX perform over the long term?
See historical performance and comparison